세계 헵시딘(Hepcidin) 시장 규모 : 용도별, 지역별 및 예측별

Global Hepcidin Market Analysis

Hepcidin Market size was valued at USD 368 Million in 2025 and is projected to reach USD 598 Million by 2033, growing at a CAGR of 11.8% from 2027 to 2033.

The Global Hepcidin Market centers on therapeutic agents targeting this key iron metabolism regulator to address anemia, iron overload disorders, and inflammatory conditions. Hepcidin acts as the master switch controlling iron absorption and release from cellular stores, making it a prime target for novel treatments addressing unmet needs in chronic kidney disease, sickle cell anemia, beta-thalassemia, and cancer-related anemia where traditional erythropoietin therapies prove ineffective or exacerbate iron accumulation.

Pipeline candidates employ diverse mechanisms including monoclonal antibodies neutralizing hepcidin activity, small molecule agonists/antagonists modulating expression, Anticalin proteins binding circulating hepcidin, and RNAi therapeutics silencing hepatic production, with clinical-stage programs demonstrating improved hemoglobin levels and reduced transfusion requirements in refractory patient populations. North America and Europe lead through established biotech innovation hubs and favorable reimbursement frameworks, while Asia-Pacific accelerates via rising chronic disease prevalence, expanding clinical trial infrastructure, and growing biopharma R&D investments.

Global Hepcidin Market Definition

The Global Hepcidin Market encompasses therapeutic agents, diagnostic assays, and research tools targeting hepcidin, the liver-produced peptide hormone serving as the master regulator of systemic iron homeostasis. Hepcidin maintains iron balance by binding ferroportin-the sole cellular iron exporter located on enterocytes, macrophages, and hepatocytes triggering its lysosomal degradation and thereby blocking dietary iron absorption while sequestering iron within reticuloendothelial stores during infection or iron excess.

This antimicrobial mechanism evolved as innate immunity defense, limiting pathogen iron access through nutritional immunity, while pathologically elevated levels during chronic inflammation cause functional iron deficiency anemia characteristic of cancer, CKD, and autoimmune diseases. Market products span monoclonal antibodies neutralizing circulating hepcidin, mini-hepcidin agonists treating hereditary hemochromatosis, ELISA kits quantifying serum levels for differential anemia diagnosis, and mass spectrometry reagents supporting proteomics research into iron-related disorders spanning beta-thalassemia transfusion dependency to polycythemia vera iron withholding.

Global Hepcidin Market Overview

The Global Hepcidin Market primarily focuses on diagnostic assays and emerging therapeutics targeting this critical iron-regulatory hormone. Hepcidin testing enables precise anemia classification distinguishing iron deficiency from anemia of chronic disease, while therapeutic candidates progress through clinical development to modulate hepcidin activity in beta-thalassemia, chronic kidney disease, and cancer-related anemia where traditional erythropoietin stimulation proves ineffective or counterproductive.

North America leads through advanced diagnostic infrastructure and biotech innovation hubs, Europe follows with established reimbursement frameworks for specialized assays, and Asia-Pacific accelerates via rising chronic disease prevalence and expanding clinical trial networks supporting late-stage hepcidin modulators. Hospitals and diagnostic laboratories constitute primary end-users performing ELISA quantification and mass spectrometry validation, with research institutions driving biomarker discovery across inflammatory, infectious, and neoplastic conditions exhibiting hepcidin dysregulation.

Global Hepcidin Market: Segmentation Analysis.

The Global Hepcidin Market is segmented based on Application, and region.

Hepcidin Market, By Application

Acute Inflammation

Anemia

Iron Deficiency Anemia

Sickle Cell Disease

Others

Global Hepcidin Market by application encompasses acute inflammation, anemia, iron deficiency anemia, sickle cell disease, and others. Acute inflammation testing quantifies hepcidin elevation during sepsis or cytokine storms blocking ferroportin-mediated iron release, creating functional deficiency despite adequate stores. Anemia diagnostics differentiate true iron deficiency from anemia of chronic disease where inappropriately high hepcidin sequesters iron in macrophages. Iron deficiency anemia applications validate low hepcidin levels confirming absorption defects amenable to oral supplementation. Sickle cell disease programs target hepcidin suppression to improve ineffective erythropoiesis and reduce transfusion dependence in hemoglobinopathy patients. Other applications span hemochromatosis treatment via hepcidin agonists, polycythemia vera iron restriction, cancer chemotherapy-induced anemia management, and chronic kidney disease dialysis optimization where hepcidin dysregulation complicates ESA responsiveness.

Hepcidin Market, By Geography

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Global Hepcidin Market by geography reveals North America leading through advanced diagnostic infrastructure and biotech innovation hubs supporting clinical trials for hepcidin modulators. North America dominates with widespread ELISA adoption in hospital laboratories for anemia subtyping and established reimbursement for specialized iron studies. Europe follows leveraging EMA-approved research use only assays and national health systems prioritizing cost-effective anemia diagnostics distinguishing treatable iron deficiency from inflammatory blockade.

Asia Pacific accelerates rapidly via rising chronic kidney disease prevalence, expanding clinical laboratory networks, and government-sponsored hemoglobinopathy screening programs targeting thalassemia and sickle cell populations. Latin America concentrates demand around Brazilian public health initiatives for neglected anemias and Mexican private diagnostic chains serving affluent chronic disease patients. Middle East and Africa focus on Gulf state quaternary centers managing expatriate hemoglobinopathies alongside South African reference laboratories addressing high HIV/tuberculosis-associated anemia of chronic inflammation where hepcidin quantification guides therapeutic decisions.

Key Players

The Global Hepcidin Market is highly fragmented with the presence of a large number of players. Some of the major companies include Daiichi Sankyo Co Ltd, Pieris Pharmaceuticals Inc, Protagonist Therapeutics Inc, Noxxon Pharma AG, Novartis AG, Amgen Inc, FibroGen Inc, Ixeris, Humabs BioMed, Hepcidin Therapeutics, among others.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA SOURCES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL HEPCIDIN MARKET OVERVIEW
• 3.2 GLOBAL HEPCIDIN MARKET ESTIMATES AND FORECAST (USD MILLION)
• 3.3 GLOBAL HEPCIDIN MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL HEPCIDIN MARKET ABSOLUTE MARKET OPPORTUNITY
• 3.6 GLOBAL HEPCIDIN MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL HEPCIDIN MARKET ATTRACTIVENESS ANALYSIS, BY APPLICATION
• 3.8 GLOBAL HEPCIDIN MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
• 3.9 GLOBAL HEPCIDIN MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.10 GLOBAL HEPCIDIN MARKET, BY APPLICATION (USD MILLION)
• 3.11 GLOBAL HEPCIDIN MARKET, BY END-USER (USD MILLION)
• 3.12 GLOBAL HEPCIDIN MARKET, BY GEOGRAPHY (USD MILLION)
• 3.13 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL HEPCIDIN MARKET EVOLUTION
• 4.2 GLOBAL HEPCIDIN MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE TYPES
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY APPLICATION

• 5.1 OVERVIEW
• 5.2 GLOBAL HEPCIDIN MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY APPLICATION
• 5.3 ACUTE INFLAMMATION
• 5.4 ANEMIA
• 5.5 IRON DEFICIENCY ANEMIA
• 5.6 SICKLE CELL DISEASE
• 5.7 OTHERS

6 MARKET, BY GEOGRAPHY

• 6.1 OVERVIEW
• 6.2 NORTH AMERICA
  • 6.2.1 U.S.
  • 6.2.2 CANADA
  • 6.2.3 MEXICO
• 6.3 EUROPE
  • 6.3.1 GERMANY
  • 6.3.2 U.K.
  • 6.3.3 FRANCE
  • 6.3.4 ITALY
  • 6.3.5 SPAIN
  • 6.3.6 REST OF EUROPE
• 6.4 ASIA PACIFIC
  • 6.4.1 CHINA
  • 6.4.2 JAPAN
  • 6.4.3 INDIA
  • 6.4.4 REST OF ASIA PACIFIC
• 6.5 LATIN AMERICA
  • 6.5.1 BRAZIL
  • 6.5.2 ARGENTINA
  • 6.5.3 REST OF LATIN AMERICA
• 6.6 MIDDLE EAST AND AFRICA
  • 6.6.1 UAE
  • 6.6.2 SAUDI ARABIA
  • 6.6.3 SOUTH AFRICA
  • 6.6.4 REST OF MIDDLE EAST AND AFRICA

7 COMPETITIVE LANDSCAPE

• 7.1 OVERVIEW
• 7.2 KEY DEVELOPMENT STRATEGIES
• 7.3 COMPANY REGIONAL FOOTPRINT
• 7.4 ACE MATRIX
  • 7.5.1 ACTIVE
  • 7.5.2 CUTTING EDGE
  • 7.5.3 EMERGING
  • 7.5.4 INNOVATORS

8 COMPANY PROFILES

• 8.1 OVERVIEW
• 8.2 DAIICHI SANKYO CO LTD
• 8.3 PIERIS PHARMACEUTICALS INC
• 8.4 PROTAGONIST THERAPEUTICS INC
• 8.5 NOXXON PHARMA AG
• 8.6 NOVARTIS AG
• 8.8 AMGEN INC
• 8.9 FIBROGEN INC
• 8.10 IXERIS
• 8.11 HUMABS BIOMED
• 8.12 HEPCIDIN THERAPEUTICS